Moderna is front and center in the race to develop a vaccine for Covid-19. In a press release on Monday it stated, “With today’s positive interim Phase 1 data and the positive data in the mouse challenge model, the Moderna team continues to focus on moving as fast as safely possible to start our pivotal Phase 3 study in July and, if successful, file a BLA (Biologics License Application).”
The company has also been cited by Dr. Anthony Fauci who expressed “cautious optimism” Friday about the initial results from a coronavirus vaccine trial — which were widely celebrated this week — and said it remains “conceivable” that a vaccine for the deadly pathogen could be available by the end of the year per an NPR report.
[I am not in a position to offer judgment on the medical aspects of Moderna’s trial results and outlook. What I am providing are the historical financial results of the company, how the stock is valued and what it could mean for the shares.]
Historical financial results
Moderna has not sold any products to generate revenue. It has relied upon collaboration revenue from other companies and grants to…
This News From Feed news.google title “Buyer Beware: Covid-19 Vaccine Maker Moderna Is Valued In The Stratosphere – Forbes”
geico insurance,instant auto insurance quote,get auto insurance online,purchase auto insurance online,auto insurance quotes online,farmers insurance,farm insurance,a car insurance